Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Aurinia Pharmaceuticals Inc.AUPH · Entity 4463 | Director | June 04, 2026 | June 08, 2026 |
| HERON THERAPEUTICS, INC. /DE/HRTX · Entity 7133 | Director | January 30, 2026 | February 03, 2026 |
| Odonate Therapeutics, Inc.ODT · Entity 132524 | Director | December 29, 2020 | December 31, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Aurinia Pharmaceuticals Inc.
Report date June 04, 2026 · Filed June 08, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.67 · Expires 2036-06-04 | Direct | 23,931 |
Reported balance
After 2026-06-04 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-04 · Grant · Acquired 23,931 · Balance 23,931 F1: The options shall vest one year from date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: The options shall vest one year from date of grant.
HERON THERAPEUTICS, INC. /DE/
Report date January 30, 2026 · Filed February 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 53,960 |
Reported balance
After 2026-01-30 transaction · row 1
1 source rowRow 1 · 2026-01-30 · Grant · Acquired 53,960 · Balance 53,960 F1: The shares were granted as restricted stock units which vest in full on January 30, 2027. Each restricted stock unit represents a contigent right to receive one share of common stock. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares were granted as restricted stock units which vest in full on January 30, 2027. Each restricted stock unit represents a contigent right to receive one share of common stock.
Odonate Therapeutics, Inc.
Report date December 29, 2020 · Filed December 31, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 3,000 |
Reported balance
After 2020-12-29 transaction · row 1
1 source rowRow 1 · 2020-12-29 · Purchase · Acquired 3,000 · Balance 3,000 F1: These shares were acquired through the open market. |
Filing footnotes · ownership attribution and instrument terms
F1: These shares were acquired through the open market.
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
LA JOLLA PHARMACEUTICAL CO
Report date August 22, 2022 · Filed August 24, 2022
Section 16 reporting ended · disclosed 2022-08-24. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2022-08-22 transaction · row 1
1 source rowRow 1 · 2022-08-22 · Disposition to issuer · Disposed 12,000 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of July 10, 2022, by and among the Issuer, Innoviva, Inc., a Delaware corporation ("Parent"), and Innoviva Acquisition Sub, Inc., a Delaware corporation and a wholly-owned subsidiary of the Parent ("Purchaser"), to which Purchaser completed a tender offer for shares of common stock of the Issuer, $0.0001 par value per share (each, a "Share"), and thereafter merged with and into the Issuer (the "Merger") effective as of August 22, 2022 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was converted into the right to receive $6.23 per Share, in cash, without interest (the "Offer Price") and subject to any withholding of taxes, upon the terms and subject to the conditions of the Merger Agreement. From and after the Effective Time, all Shares were no longer outstanding and were automatically cancelled. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.00 | Direct | 0 |
Reported balance
After 2022-08-22 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2022-08-22 · Disposition to issuer · Disposed 18,000 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an "Issuer Stock Option") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.84 | Direct | 0 |
Reported balance
After 2022-08-22 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2022-08-22 · Disposition to issuer · Disposed 19,000 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an "Issuer Stock Option") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $19.69 | Direct | 0 |
Reported balance
After 2022-08-22 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2022-08-22 · Disposition to issuer · Disposed 10,000 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an "Issuer Stock Option") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $28.24 | Direct | 0 |
Reported balance
After 2022-08-22 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2022-08-22 · Disposition to issuer · Disposed 10,000 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an "Issuer Stock Option") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $19.19 | Direct | 0 |
Reported balance
After 2022-08-22 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2022-08-22 · Disposition to issuer · Disposed 10,000 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an "Issuer Stock Option") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $28.10 | Direct | 0 |
Reported balance
After 2022-08-22 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2022-08-22 · Disposition to issuer · Disposed 10,000 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an "Issuer Stock Option") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.99 | Direct | 0 |
Reported balance
After 2022-08-22 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2022-08-22 · Disposition to issuer · Disposed 12,000 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an "Issuer Stock Option") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.25 | Direct | 0 |
Reported balance
After 2022-08-22 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2022-08-22 · Disposition to issuer · Disposed 30,000 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an "Issuer Stock Option") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.53 | Direct | 0 |
Reported balance
After 2022-08-22 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2022-08-22 · Disposition to issuer · Disposed 30,000 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an "Issuer Stock Option") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.81 | Direct | 0 |
Reported balance
After 2022-08-22 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2022-08-22 · Disposition to issuer · Disposed 30,000 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an "Issuer Stock Option") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option. |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of July 10, 2022, by and among the Issuer, Innoviva, Inc., a Delaware corporation ("Parent"), and Innoviva Acquisition Sub, Inc., a Delaware corporation and a wholly-owned subsidiary of the Parent ("Purchaser"), to which Purchaser completed a tender offer for shares of common stock of the Issuer, $0.0001 par value per share (each, a "Share"), and thereafter merged with and into the Issuer (the "Merger") effective as of August 22, 2022 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was converted into the right to receive $6.23 per Share, in cash, without interest (the "Offer Price") and subject to any withholding of taxes, upon the terms and subject to the conditions of the Merger Agreement. From and after the Effective Time, all Shares were no longer outstanding and were automatically cancelled.
F2: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an "Issuer Stock Option") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option.
Mirati Therapeutics, Inc.
Report date January 23, 2024 · Filed January 24, 2024
Section 16 reporting ended · disclosed 2024-01-24. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2024-01-23 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2024-01-23 · Disposition to issuer · Disposed 6,021 · Balance 11,252 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of October 8, 2023, among the Issuer, Bristol-Myers Squibb Company ("BMS"), and Vineyard Merger Sub Inc., a wholly owned subsidiary of BMS ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer (the "Merger"), effective as of January 23, 2024 (such date and time of such Merger, the "Effective Time"), with the Issuer surviving the Merger as a wholly owned subsidiary of BMS. F2: At the Effective Time, each issued and outstanding share of common stock of the Issuer ("Company Common Stock") reported in this Form 4 was converted into the right to receive (A) $58.00 per share in cash (the "Closing Consideration") and (B) one contingent value right (a "CVR"), which represents the right to receive the Milestone Payment (as such term is defined in the CVR Agreement, which is itself defined in the Merger Agreement) (the consideration contemplated by (A) and (B), together, the "Merger Consideration"), without interest and subject to any withholding taxes. Row 2 · 2024-01-23 · Disposition to issuer · Disposed 4,444 · Balance 6,808 F3: Pursuant to the Merger Agreement, at the Effective Time, each of these restricted stock units ("RSUs") that was outstanding as of immediately prior to the Effective Time was cancelled and the Reporting Person was entitled to receive the Merger Consideration in respect of each such RSU. Row 3 · 2024-01-23 · Disposition to issuer · Disposed 6,808 · Balance 0 F4: Pursuant to the Merger Agreement and the Company Equity Plans (as such term is defined in the Merger Agreement), at the Effective Time, each of these RSUs that was outstanding as of immediately prior to the Effective Time was cancelled and converted into the right to receive a cash award of BMS in an amount equal to the product of the number of restricted stock units subject to such RSU immediately prior to the Effective Time and the last trading price of a share of Company Common Stock before the Effective Time (the "Converted Cash Award"). Following the Effective Time, the Converted Cash Award will be subject to the same terms and conditions applicable to such Issuer RSUs, including with respect to vesting. |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $15.72 · Expires 2026-05-17 | Direct | 0 |
Reported balance
After 2024-01-23 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2024-01-23 · Disposition to issuer · Disposed 10,000 · Balance 0 F5: Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a "Company Option") that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price ("Per Share Exercise Price") that was less than the Closing Consideration, was cancelled and converted into the right to receive the sum of (A) a cash payment, without interest, equal to (x) the excess of (1) the Closing Consideration over (2) the Per Share Exercise Price, multiplied by (y) the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time (without regard to vesting) and (B) one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time (without regard to vesting). |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $20.54 · Expires 2024-09-08 | Direct | 0 |
Reported balance
After 2024-01-23 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2024-01-23 · Disposition to issuer · Disposed 18,000 · Balance 0 F5: Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a "Company Option") that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price ("Per Share Exercise Price") that was less than the Closing Consideration, was cancelled and converted into the right to receive the sum of (A) a cash payment, without interest, equal to (x) the excess of (1) the Closing Consideration over (2) the Per Share Exercise Price, multiplied by (y) the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time (without regard to vesting) and (B) one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time (without regard to vesting). |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $27.00 · Expires 2028-01-17 | Direct | 0 |
Reported balance
After 2024-01-23 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2024-01-23 · Disposition to issuer · Disposed 10,000 · Balance 0 F5: Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a "Company Option") that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price ("Per Share Exercise Price") that was less than the Closing Consideration, was cancelled and converted into the right to receive the sum of (A) a cash payment, without interest, equal to (x) the excess of (1) the Closing Consideration over (2) the Per Share Exercise Price, multiplied by (y) the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time (without regard to vesting) and (B) one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time (without regard to vesting). |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $45.66 · Expires 2033-01-20 | Direct | 0 |
Reported balance
After 2024-01-23 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2024-01-23 · Disposition to issuer · Disposed 7,520 · Balance 0 F5: Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a "Company Option") that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price ("Per Share Exercise Price") that was less than the Closing Consideration, was cancelled and converted into the right to receive the sum of (A) a cash payment, without interest, equal to (x) the excess of (1) the Closing Consideration over (2) the Per Share Exercise Price, multiplied by (y) the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time (without regard to vesting) and (B) one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time (without regard to vesting). |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $64.14 · Expires 2029-01-16 | Direct | 0 |
Reported balance
After 2024-01-23 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2024-01-23 · Disposition to issuer · Disposed 11,000 · Balance 0 F6: Pursuant to the Merger Agreement, at the Effective Time, each Company Option that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a Per Share Exercise Price that was equal to or greater than the Closing Consideration, but was less than the sum of the Closing Consideration and the maximum amount payable in respect of one CVR (the "Maximum Total Consideration"), was cancelled and converted into the right to receive a cash payment equal to (A) the excess of (x) the sum of (i) the Closing Consideration plus (ii) the actual Milestone Payment, if any, made in respect of one CVR over (y) the Per Share Exercise Price, multiplied by (B) the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time (without regard to vesting). F7: Such payment will be made if, and only if, a Milestone Payment is made in respect of a CVR and will be made at the same time the Milestone Payment is made to holders of CVRs. If the CVR is terminated or expires without payment, no payment will be made with respect to any such Company Option. |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of October 8, 2023, among the Issuer, Bristol-Myers Squibb Company ("BMS"), and Vineyard Merger Sub Inc., a wholly owned subsidiary of BMS ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer (the "Merger"), effective as of January 23, 2024 (such date and time of such Merger, the "Effective Time"), with the Issuer surviving the Merger as a wholly owned subsidiary of BMS.
F2: At the Effective Time, each issued and outstanding share of common stock of the Issuer ("Company Common Stock") reported in this Form 4 was converted into the right to receive (A) $58.00 per share in cash (the "Closing Consideration") and (B) one contingent value right (a "CVR"), which represents the right to receive the Milestone Payment (as such term is defined in the CVR Agreement, which is itself defined in the Merger Agreement) (the consideration contemplated by (A) and (B), together, the "Merger Consideration"), without interest and subject to any withholding taxes.
F3: Pursuant to the Merger Agreement, at the Effective Time, each of these restricted stock units ("RSUs") that was outstanding as of immediately prior to the Effective Time was cancelled and the Reporting Person was entitled to receive the Merger Consideration in respect of each such RSU.
F4: Pursuant to the Merger Agreement and the Company Equity Plans (as such term is defined in the Merger Agreement), at the Effective Time, each of these RSUs that was outstanding as of immediately prior to the Effective Time was cancelled and converted into the right to receive a cash award of BMS in an amount equal to the product of the number of restricted stock units subject to such RSU immediately prior to the Effective Time and the last trading price of a share of Company Common Stock before the Effective Time (the "Converted Cash Award"). Following the Effective Time, the Converted Cash Award will be subject to the same terms and conditions applicable to such Issuer RSUs, including with respect to vesting.
F5: Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a "Company Option") that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price ("Per Share Exercise Price") that was less than the Closing Consideration, was cancelled and converted into the right to receive the sum of (A) a cash payment, without interest, equal to (x) the excess of (1) the Closing Consideration over (2) the Per Share Exercise Price, multiplied by (y) the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time (without regard to vesting) and (B) one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time (without regard to vesting).
F6: Pursuant to the Merger Agreement, at the Effective Time, each Company Option that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a Per Share Exercise Price that was equal to or greater than the Closing Consideration, but was less than the sum of the Closing Consideration and the maximum amount payable in respect of one CVR (the "Maximum Total Consideration"), was cancelled and converted into the right to receive a cash payment equal to (A) the excess of (x) the sum of (i) the Closing Consideration plus (ii) the actual Milestone Payment, if any, made in respect of one CVR over (y) the Per Share Exercise Price, multiplied by (B) the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time (without regard to vesting).
F7: Such payment will be made if, and only if, a Milestone Payment is made in respect of a CVR and will be made at the same time the Milestone Payment is made to holders of CVRs. If the CVR is terminated or expires without payment, no payment will be made with respect to any such Company Option.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 04, 2026 Filed Jun 8, 2026 20:14 UTC | Aurinia Pharmaceuticals Inc. AUPH · Entity 4463 | GrantDirector Stock Option (right to buy) · Derivative | 23,931 | $0.00 Strike: $15.67 | $0.00 |
DisclosureSEC source: 0001370348-26-000002 · wk-form4_1780949641.xml · derivative · entry 1 Johnson Craig A · CIK 0001370348 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,931 Underlying: Common Shares · 23,931 shares Expires 2036-06-04 F1 · derivative.exercise_date: The options shall vest one year from date of grant. Read SEC document |
| January 30, 2026 Filed Feb 3, 2026 15:00 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | GrantCommon Stock | 53,960 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-034629 · ownership.xml · nonDerivative · entry 1 Johnson Craig A · CIK 0001370348 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 53,960 F1 · shares: The shares were granted as restricted stock units which vest in full on January 30, 2027. Each restricted stock unit represents a contigent right to receive one share of common stock. Read SEC document |
| November 21, 2025 Filed Nov 24, 2025 22:17 UTC | Aurinia Pharmaceuticals Inc. AUPH · Entity 4463 | Tax withholdingCommon Shares | 6,039 | $15.68 | $94,691.52 |
DisclosureSEC source: 0001370348-25-000004 · wk-form4_1764022670.xml · nonDerivative · entry 1 Johnson Craig A · CIK 0001370348 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,592 F1 · shares: Represents shares withheld to satisfy tax withholding obligations upon the vesting of restricted stock units. Read SEC document |
| May 16, 2025 Filed May 16, 2025 21:05 UTC | Aurinia Pharmaceuticals Inc. AUPH · Entity 4463 | GrantDirector Stock Option (right to buy) · Derivative | 37,485 | $0.00 Strike: $8.15 | $0.00 |
DisclosureSEC source: 0001600620-25-000077 · wk-form4_1747429513.xml · derivative · entry 1 Johnson Craig A · CIK 0001370348 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,485 Underlying: Common Shares · 37,485 shares Expires 2035-05-16 F1 · derivative.exercise_date: The options shall vest one year from date of grant. Read SEC document |
| January 31, 2025 Filed Feb 4, 2025 22:30 UTC Amendment | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | GrantStock Option (Right to Buy) · Derivative | 35,900 | $0.00 Strike: $1.70 | $0.00 |
DisclosureSEC source: 0000950170-25-013756 · ownership.xml · derivative · entry 2 Johnson Craig A · CIK 0001370348 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,900 Underlying: Common Stock · 35,900 shares Expires 2035-01-31 F2 · derivative.exercise_date: The stock options vest and become exercisable in 12 equal monthly installments beginning one month after the date of grant. Read SEC document |
| January 31, 2025 Filed Feb 4, 2025 22:30 UTC Amendment | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | GrantCommon Stock | 17,950 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-013756 · ownership.xml · nonDerivative · entry 1 Johnson Craig A · CIK 0001370348 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 83,770 F1 · shares: The shares were granted as restricted stock units which vest in full on January 31, 2026. Each restricted stock unit represents a contigent right to receive one share of common stock. Read SEC document |
| January 30, 2025 Filed Feb 3, 2025 16:41 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | GrantStock Option (Right to Buy) · Derivative | 35,900 | $1.73 Strike: $1.73 | $62,107.00 |
DisclosureSEC source: 0000950170-25-012101 · ownership.xml · derivative · entry 2 Johnson Craig A · CIK 0001370348 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,900 Underlying: Common Stock · 35,900 shares Expires 2035-01-30 F2 · derivative.exercise_date: The stock options vest and become exercisable in 12 equal monthly installments beginning one month after the date of grant. Read SEC document |
| January 30, 2025 Filed Feb 3, 2025 16:41 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | GrantCommon Stock | 17,950 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-012101 · ownership.xml · nonDerivative · entry 1 Johnson Craig A · CIK 0001370348 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 83,770 F1 · shares: The shares were granted as restricted stock units which vest in full on January 30, 2026. Each restricted stock unit represents a contigent right to receive one share of common stock. Read SEC document |
| November 21, 2024 Filed Nov 25, 2024 21:33 UTC | Aurinia Pharmaceuticals Inc. AUPH · Entity 4463 | GrantDirector Stock Option (right to buy) · Derivative | 31,688 | $0.00 Strike: $8.24 | $0.00 |
DisclosureSEC source: 0001600620-24-000122 · wk-form4_1732570412.xml · derivative · entry 2 Johnson Craig A · CIK 0001370348 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,688 Underlying: Common Shares · 31,688 shares Expires 2034-11-21 F2 · derivative.exercise_date: The options shall vest one year from date of grant. Read SEC document |
| November 21, 2024 Filed Nov 25, 2024 21:33 UTC | Aurinia Pharmaceuticals Inc. AUPH · Entity 4463 | GrantCommon Shares | 20,631 | $0.00 | $0.00 |
DisclosureSEC source: 0001600620-24-000122 · wk-form4_1732570412.xml · nonDerivative · entry 1 Johnson Craig A · CIK 0001370348 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,631 F1 · shares: Represents grant of Restricted Stock Units (RSUs) payable solely in common shares of the Issuer. The shares subject to the RSUs shall vest one year from date of grant. Read SEC document |
| January 23, 2024 Filed Jan 24, 2024 01:37 UTC | Mirati Therapeutics, Inc. MRTX · Entity 94908 | Disposition to issuerOption to Purchase Common Stock · Derivative | 11,000 | Not disclosed Strike: $64.14 | Not disclosed |
DisclosureSEC source: 0001140361-24-003534 · form4.xml · derivative · entry 8 Johnson Craig A · CIK 0001370348 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 11,000 shares Expires 2029-01-16 F6 · price: Pursuant to the Merger Agreement, at the Effective Time, each Company Option that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a Per Share Exercise Price that was equal to or greater than the Closing Consideration, but was less than the sum of the Closing Consideration and the maximum amount payable in respect of one CVR (the "Maximum Total Consideration"), was cancelled and converted into the right to receive a cash payment equal to (A) the excess of (x) the sum of (i) the Closing Consideration plus (ii) the actual Milestone Payment, if any, made in respect of one CVR over (y) the Per Share Exercise Price, multiplied by (B) the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time (without regard to vesting). F7 · price: Such payment will be made if, and only if, a Milestone Payment is made in respect of a CVR and will be made at the same time the Milestone Payment is made to holders of CVRs. If the CVR is terminated or expires without payment, no payment will be made with respect to any such Company Option. F6 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each Company Option that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a Per Share Exercise Price that was equal to or greater than the Closing Consideration, but was less than the sum of the Closing Consideration and the maximum amount payable in respect of one CVR (the "Maximum Total Consideration"), was cancelled and converted into the right to receive a cash payment equal to (A) the excess of (x) the sum of (i) the Closing Consideration plus (ii) the actual Milestone Payment, if any, made in respect of one CVR over (y) the Per Share Exercise Price, multiplied by (B) the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time (without regard to vesting). Read SEC document |
| January 23, 2024 Filed Jan 24, 2024 01:37 UTC | Mirati Therapeutics, Inc. MRTX · Entity 94908 | Disposition to issuerOption to Purchase Common Stock · Derivative | 7,520 | Not disclosed Strike: $45.66 | Not disclosed |
DisclosureSEC source: 0001140361-24-003534 · form4.xml · derivative · entry 7 Johnson Craig A · CIK 0001370348 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,520 shares Expires 2033-01-20 F5 · price: Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a "Company Option") that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price ("Per Share Exercise Price") that was less than the Closing Consideration, was cancelled and converted into the right to receive the sum of (A) a cash payment, without interest, equal to (x) the excess of (1) the Closing Consideration over (2) the Per Share Exercise Price, multiplied by (y) the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time (without regard to vesting) and (B) one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time (without regard to vesting). F5 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a "Company Option") that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price ("Per Share Exercise Price") that was less than the Closing Consideration, was cancelled and converted into the right to receive the sum of (A) a cash payment, without interest, equal to (x) the excess of (1) the Closing Consideration over (2) the Per Share Exercise Price, multiplied by (y) the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time (without regard to vesting) and (B) one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time (without regard to vesting). Read SEC document |
| January 23, 2024 Filed Jan 24, 2024 01:37 UTC | Mirati Therapeutics, Inc. MRTX · Entity 94908 | Disposition to issuerOption to Purchase Common Stock · Derivative | 10,000 | Not disclosed Strike: $27.00 | Not disclosed |
DisclosureSEC source: 0001140361-24-003534 · form4.xml · derivative · entry 6 Johnson Craig A · CIK 0001370348 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2028-01-17 F5 · price: Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a "Company Option") that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price ("Per Share Exercise Price") that was less than the Closing Consideration, was cancelled and converted into the right to receive the sum of (A) a cash payment, without interest, equal to (x) the excess of (1) the Closing Consideration over (2) the Per Share Exercise Price, multiplied by (y) the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time (without regard to vesting) and (B) one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time (without regard to vesting). F5 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a "Company Option") that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price ("Per Share Exercise Price") that was less than the Closing Consideration, was cancelled and converted into the right to receive the sum of (A) a cash payment, without interest, equal to (x) the excess of (1) the Closing Consideration over (2) the Per Share Exercise Price, multiplied by (y) the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time (without regard to vesting) and (B) one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time (without regard to vesting). Read SEC document |
| January 23, 2024 Filed Jan 24, 2024 01:37 UTC | Mirati Therapeutics, Inc. MRTX · Entity 94908 | Disposition to issuerOption to Purchase Common Stock · Derivative | 18,000 | Not disclosed Strike: $20.54 | Not disclosed |
DisclosureSEC source: 0001140361-24-003534 · form4.xml · derivative · entry 5 Johnson Craig A · CIK 0001370348 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 18,000 shares Expires 2024-09-08 F5 · price: Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a "Company Option") that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price ("Per Share Exercise Price") that was less than the Closing Consideration, was cancelled and converted into the right to receive the sum of (A) a cash payment, without interest, equal to (x) the excess of (1) the Closing Consideration over (2) the Per Share Exercise Price, multiplied by (y) the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time (without regard to vesting) and (B) one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time (without regard to vesting). F5 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a "Company Option") that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price ("Per Share Exercise Price") that was less than the Closing Consideration, was cancelled and converted into the right to receive the sum of (A) a cash payment, without interest, equal to (x) the excess of (1) the Closing Consideration over (2) the Per Share Exercise Price, multiplied by (y) the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time (without regard to vesting) and (B) one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time (without regard to vesting). Read SEC document |
| January 23, 2024 Filed Jan 24, 2024 01:37 UTC | Mirati Therapeutics, Inc. MRTX · Entity 94908 | Disposition to issuerOption to Purchase Common Stock · Derivative | 10,000 | Not disclosed Strike: $15.72 | Not disclosed |
DisclosureSEC source: 0001140361-24-003534 · form4.xml · derivative · entry 4 Johnson Craig A · CIK 0001370348 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2026-05-17 F5 · price: Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a "Company Option") that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price ("Per Share Exercise Price") that was less than the Closing Consideration, was cancelled and converted into the right to receive the sum of (A) a cash payment, without interest, equal to (x) the excess of (1) the Closing Consideration over (2) the Per Share Exercise Price, multiplied by (y) the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time (without regard to vesting) and (B) one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time (without regard to vesting). F5 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a "Company Option") that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price ("Per Share Exercise Price") that was less than the Closing Consideration, was cancelled and converted into the right to receive the sum of (A) a cash payment, without interest, equal to (x) the excess of (1) the Closing Consideration over (2) the Per Share Exercise Price, multiplied by (y) the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time (without regard to vesting) and (B) one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time (without regard to vesting). Read SEC document |
| January 23, 2024 Filed Jan 24, 2024 01:37 UTC | Mirati Therapeutics, Inc. MRTX · Entity 94908 | Disposition to issuerCommon Stock | 6,808 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-24-003534 · form4.xml · nonDerivative · entry 3 Johnson Craig A · CIK 0001370348 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F4 · price: Pursuant to the Merger Agreement and the Company Equity Plans (as such term is defined in the Merger Agreement), at the Effective Time, each of these RSUs that was outstanding as of immediately prior to the Effective Time was cancelled and converted into the right to receive a cash award of BMS in an amount equal to the product of the number of restricted stock units subject to such RSU immediately prior to the Effective Time and the last trading price of a share of Company Common Stock before the Effective Time (the "Converted Cash Award"). Following the Effective Time, the Converted Cash Award will be subject to the same terms and conditions applicable to such Issuer RSUs, including with respect to vesting. Read SEC document |
| January 23, 2024 Filed Jan 24, 2024 01:37 UTC | Mirati Therapeutics, Inc. MRTX · Entity 94908 | Disposition to issuerCommon Stock | 4,444 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-24-003534 · form4.xml · nonDerivative · entry 2 Johnson Craig A · CIK 0001370348 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,808 F3 · price: Pursuant to the Merger Agreement, at the Effective Time, each of these restricted stock units ("RSUs") that was outstanding as of immediately prior to the Effective Time was cancelled and the Reporting Person was entitled to receive the Merger Consideration in respect of each such RSU. Read SEC document |
| January 23, 2024 Filed Jan 24, 2024 01:37 UTC | Mirati Therapeutics, Inc. MRTX · Entity 94908 | Disposition to issuerCommon Stock | 6,021 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-24-003534 · form4.xml · nonDerivative · entry 1 Johnson Craig A · CIK 0001370348 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,252 F1 · price: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of October 8, 2023, among the Issuer, Bristol-Myers Squibb Company ("BMS"), and Vineyard Merger Sub Inc., a wholly owned subsidiary of BMS ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer (the "Merger"), effective as of January 23, 2024 (such date and time of such Merger, the "Effective Time"), with the Issuer surviving the Merger as a wholly owned subsidiary of BMS. F2 · price: At the Effective Time, each issued and outstanding share of common stock of the Issuer ("Company Common Stock") reported in this Form 4 was converted into the right to receive (A) $58.00 per share in cash (the "Closing Consideration") and (B) one contingent value right (a "CVR"), which represents the right to receive the Milestone Payment (as such term is defined in the CVR Agreement, which is itself defined in the Merger Agreement) (the consideration contemplated by (A) and (B), together, the "Merger Consideration"), without interest and subject to any withholding taxes. Read SEC document |
| January 19, 2024 Filed Jan 20, 2024 02:03 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | GrantStock Option (Right to Buy) · Derivative | 83,685 | $0.00 Strike: $2.09 | $0.00 |
DisclosureSEC source: 0001209191-24-001979 · doc4.xml · derivative · entry 2 Johnson Craig A · CIK 0001370348 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 83,685 Underlying: Common Stock · 83,685 shares Expires 2034-01-19 F2 · derivative.exercise_date: The stock options vest and become exercisable in 12 equal monthly installments beginning one month after the date of grant. Read SEC document |
| January 19, 2024 Filed Jan 20, 2024 02:03 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | GrantCommon Stock | 13,948 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-24-001979 · doc4.xml · nonDerivative · entry 1 Johnson Craig A · CIK 0001370348 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 65,820 F1 · shares: The shares were granted as restricted stock units which vest in full on January 19, 2025. Read SEC document |
| December 29, 2023 Filed Jan 3, 2024 23:37 UTC | Mirati Therapeutics, Inc. MRTX · Entity 94908 | GrantCommon Stock | 6,808 | $58.75 | $399,970.00 |
DisclosureSEC source: 0001628280-24-000321 · wk-form4_1704325032.xml · nonDerivative · entry 1 Johnson Craig A · CIK 0001370348 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,273 F1 · shares: Grant of Restricted Stock Units (RSUs). Shares will vest 100% on the anniversary of the grant date. Read SEC document |
| January 20, 2023 Filed Jan 24, 2023 21:19 UTC | Mirati Therapeutics, Inc. MRTX · Entity 94908 | GrantNon Qualified Stock Option (right to buy) · Derivative | 7,520 | $0.00 Strike: $45.66 | $0.00 |
DisclosureSEC source: 0001214659-23-001048 · marketforms-58260.xml · derivative · entry 2 Johnson Craig A · CIK 0001370348 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,520 Underlying: Common Stock · 7,520 shares Expires 2033-01-20 F2 · derivative.exercise_date: The shares subject to the Option vest and become exercisable in 12 equal monthly installments following the date of grant. Read SEC document |
| January 20, 2023 Filed Jan 24, 2023 21:19 UTC | Mirati Therapeutics, Inc. MRTX · Entity 94908 | GrantCommon Stock | 4,444 | $0.00 | $0.00 |
DisclosureSEC source: 0001214659-23-001048 · marketforms-58260.xml · nonDerivative · entry 1 Johnson Craig A · CIK 0001370348 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,465 F1 · shares: Grant of Restricted Stock Units (RSUs). Shares will vest 100% on the anniversary of the grant date. Read SEC document |
| December 16, 2022 Filed Dec 20, 2022 22:20 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | GrantStock Option (Right to Buy) · Derivative | 77,160 | $0.00 Strike: $2.74 | $0.00 |
DisclosureSEC source: 0001209191-22-062188 · doc4.xml · derivative · entry 2 Johnson Craig A · CIK 0001370348 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,160 Underlying: Common Stock · 77,160 shares Expires 2032-12-16 F2 · derivative.exercise_date: The stock options vest and become exercisable in 12 equal monthly installments beginning one month after the date of grant. Read SEC document |
| December 16, 2022 Filed Dec 20, 2022 22:20 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | GrantCommon Stock | 38,580 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-062188 · doc4.xml · nonDerivative · entry 1 Johnson Craig A · CIK 0001370348 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,872 F1 · shares: The shares were granted as restricted stock units which vest in full on December 16, 2023. Read SEC document |
| August 22, 2022 Filed Aug 24, 2022 20:17 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | Disposition to issuerStock Option (Right to Buy) · Derivative | 30,000 | Not disclosed Strike: $4.81 | Not disclosed |
DisclosureSEC source: 0000899243-22-029650 · doc4.xml · derivative · entry 11 Johnson Craig A · CIK 0001370348 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 30,000 shares Expires not disclosed F2 · price: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an "Issuer Stock Option") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option. F2 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an "Issuer Stock Option") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option. F2 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an "Issuer Stock Option") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option. Read SEC document |
| August 22, 2022 Filed Aug 24, 2022 20:17 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | Disposition to issuerStock Option (Right to Buy) · Derivative | 30,000 | Not disclosed Strike: $4.53 | Not disclosed |
DisclosureSEC source: 0000899243-22-029650 · doc4.xml · derivative · entry 10 Johnson Craig A · CIK 0001370348 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 30,000 shares Expires not disclosed F2 · price: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an "Issuer Stock Option") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option. F2 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an "Issuer Stock Option") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option. F2 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an "Issuer Stock Option") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option. Read SEC document |
| August 22, 2022 Filed Aug 24, 2022 20:17 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | Disposition to issuerStock Option (Right to Buy) · Derivative | 30,000 | Not disclosed Strike: $5.25 | Not disclosed |
DisclosureSEC source: 0000899243-22-029650 · doc4.xml · derivative · entry 9 Johnson Craig A · CIK 0001370348 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 30,000 shares Expires not disclosed F2 · price: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an "Issuer Stock Option") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option. F2 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an "Issuer Stock Option") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option. F2 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an "Issuer Stock Option") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option. Read SEC document |
| August 22, 2022 Filed Aug 24, 2022 20:17 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | Disposition to issuerStock Option (Right to Buy) · Derivative | 12,000 | Not disclosed Strike: $5.99 | Not disclosed |
DisclosureSEC source: 0000899243-22-029650 · doc4.xml · derivative · entry 8 Johnson Craig A · CIK 0001370348 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,000 shares Expires not disclosed F2 · price: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an "Issuer Stock Option") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option. F2 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an "Issuer Stock Option") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option. F2 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an "Issuer Stock Option") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option. Read SEC document |
| August 22, 2022 Filed Aug 24, 2022 20:17 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | Disposition to issuerStock Option (Right to Buy) · Derivative | 10,000 | Not disclosed Strike: $28.10 | Not disclosed |
DisclosureSEC source: 0000899243-22-029650 · doc4.xml · derivative · entry 7 Johnson Craig A · CIK 0001370348 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires not disclosed F2 · price: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an "Issuer Stock Option") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option. F2 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an "Issuer Stock Option") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option. F2 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an "Issuer Stock Option") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option. Read SEC document |
| August 22, 2022 Filed Aug 24, 2022 20:17 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | Disposition to issuerStock Option (Right to Buy) · Derivative | 10,000 | Not disclosed Strike: $19.19 | Not disclosed |
DisclosureSEC source: 0000899243-22-029650 · doc4.xml · derivative · entry 6 Johnson Craig A · CIK 0001370348 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires not disclosed F2 · price: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an "Issuer Stock Option") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option. F2 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an "Issuer Stock Option") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option. F2 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an "Issuer Stock Option") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option. Read SEC document |
| August 22, 2022 Filed Aug 24, 2022 20:17 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | Disposition to issuerStock Option (Right to Buy) · Derivative | 10,000 | Not disclosed Strike: $28.24 | Not disclosed |
DisclosureSEC source: 0000899243-22-029650 · doc4.xml · derivative · entry 5 Johnson Craig A · CIK 0001370348 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires not disclosed F2 · price: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an "Issuer Stock Option") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option. F2 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an "Issuer Stock Option") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option. F2 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an "Issuer Stock Option") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option. Read SEC document |
| August 22, 2022 Filed Aug 24, 2022 20:17 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | Disposition to issuerStock Option (Right to Buy) · Derivative | 10,000 | Not disclosed Strike: $19.69 | Not disclosed |
DisclosureSEC source: 0000899243-22-029650 · doc4.xml · derivative · entry 4 Johnson Craig A · CIK 0001370348 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires not disclosed F2 · price: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an "Issuer Stock Option") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option. F2 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an "Issuer Stock Option") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option. F2 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an "Issuer Stock Option") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option. Read SEC document |
| August 22, 2022 Filed Aug 24, 2022 20:17 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | Disposition to issuerStock Option (Right to Buy) · Derivative | 19,000 | Not disclosed Strike: $10.84 | Not disclosed |
DisclosureSEC source: 0000899243-22-029650 · doc4.xml · derivative · entry 3 Johnson Craig A · CIK 0001370348 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 19,000 shares Expires not disclosed F2 · price: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an "Issuer Stock Option") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option. F2 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an "Issuer Stock Option") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option. F2 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an "Issuer Stock Option") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option. Read SEC document |
| August 22, 2022 Filed Aug 24, 2022 20:17 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | Disposition to issuerStock Option (Right to Buy) · Derivative | 18,000 | Not disclosed Strike: $6.00 | Not disclosed |
DisclosureSEC source: 0000899243-22-029650 · doc4.xml · derivative · entry 2 Johnson Craig A · CIK 0001370348 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 18,000 shares Expires not disclosed F2 · price: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an "Issuer Stock Option") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option. F2 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an "Issuer Stock Option") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option. F2 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an "Issuer Stock Option") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option. Read SEC document |
| August 22, 2022 Filed Aug 24, 2022 20:17 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | Disposition to issuerCommon Stock | 12,000 | $6.23 | $74,760.00 |
DisclosureSEC source: 0000899243-22-029650 · doc4.xml · nonDerivative · entry 1 Johnson Craig A · CIK 0001370348 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of July 10, 2022, by and among the Issuer, Innoviva, Inc., a Delaware corporation ("Parent"), and Innoviva Acquisition Sub, Inc., a Delaware corporation and a wholly-owned subsidiary of the Parent ("Purchaser"), to which Purchaser completed a tender offer for shares of common stock of the Issuer, $0.0001 par value per share (each, a "Share"), and thereafter merged with and into the Issuer (the "Merger") effective as of August 22, 2022 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was converted into the right to receive $6.23 per Share, in cash, without interest (the "Offer Price") and subject to any withholding of taxes, upon the terms and subject to the conditions of the Merger Agreement. From and after the Effective Time, all Shares were no longer outstanding and were automatically cancelled. F1 · price: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of July 10, 2022, by and among the Issuer, Innoviva, Inc., a Delaware corporation ("Parent"), and Innoviva Acquisition Sub, Inc., a Delaware corporation and a wholly-owned subsidiary of the Parent ("Purchaser"), to which Purchaser completed a tender offer for shares of common stock of the Issuer, $0.0001 par value per share (each, a "Share"), and thereafter merged with and into the Issuer (the "Merger") effective as of August 22, 2022 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was converted into the right to receive $6.23 per Share, in cash, without interest (the "Offer Price") and subject to any withholding of taxes, upon the terms and subject to the conditions of the Merger Agreement. From and after the Effective Time, all Shares were no longer outstanding and were automatically cancelled. Read SEC document |
| July 08, 2022 Filed Jul 12, 2022 20:36 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 12,000 | $0.00 Strike: $3.93 | $0.00 |
DisclosureSEC source: 0001209191-22-041988 · doc4.xml · derivative · entry 2 Johnson Craig A · CIK 0001370348 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,000 shares Expires 2029-12-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: This is a cash exercise of options that vested and became exercisable on December 20, 2020. Read SEC document |
| July 08, 2022 Filed Jul 12, 2022 20:36 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | Exercise / conversionCommon Stock | 12,000 | $3.93 | $47,160.00 |
DisclosureSEC source: 0001209191-22-041988 · doc4.xml · nonDerivative · entry 1 Johnson Craig A · CIK 0001370348 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This is a cash exercise of options that vested and became exercisable on December 20, 2020. Read SEC document |
| January 14, 2022 Filed Jan 18, 2022 23:20 UTC | Mirati Therapeutics, Inc. MRTX · Entity 94908 | GrantNon Qualified Stock Option (right to buy) · Derivative | 3,688 | $0.00 Strike: $124.31 | $0.00 |
DisclosureSEC source: 0001214659-22-000846 · marketforms-55082.xml · derivative · entry 2 Johnson Craig A · CIK 0001370348 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,688 Underlying: Common Stock · 3,688 shares Expires 2032-01-13 F2 · derivative.exercise_date: The shares subject to the Option vest and become exercisable in 12 equal monthly installments following the date of grant. Read SEC document |
| January 14, 2022 Filed Jan 18, 2022 23:20 UTC | Mirati Therapeutics, Inc. MRTX · Entity 94908 | GrantCommon Stock | 2,546 | $0.00 | $0.00 |
DisclosureSEC source: 0001214659-22-000846 · marketforms-55082.xml · nonDerivative · entry 1 Johnson Craig A · CIK 0001370348 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,021 F1 · shares: Grant of Restricted Stock Units (RSUs). Shares will vest 100% on the anniversary of the grant date. Read SEC document |
| January 12, 2022 Filed Jan 14, 2022 21:00 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | GrantStock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $4.81 | $0.00 |
DisclosureSEC source: 0001209191-22-003404 · doc4.xml · derivative · entry 1 Johnson Craig A · CIK 0001370348 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2032-01-12 F1 · derivative.exercise_date: The stock options vest and become exercisable on January 12, 2023 subject to the Reporting Person's continued service to the Issuer through such date. Read SEC document |
| December 22, 2021 Filed Dec 23, 2021 23:57 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | GrantStock Option (Right to Buy) · Derivative | 20,903 | $0.00 Strike: $9.81 | $0.00 |
DisclosureSEC source: 0001209191-21-071169 · doc4.xml · derivative · entry 3 Johnson Craig A · CIK 0001370348 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,903 Underlying: Common Stock · 20,903 shares Expires 2031-12-22 F4 · derivative.exercise_date: The stock options vest and become exercisable in 12 equal monthly installments beginning one month after the date of grant. Read SEC document |
| December 22, 2021 Filed Dec 23, 2021 23:57 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | GrantCommon Stock | 10,452 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-071169 · doc4.xml · nonDerivative · entry 2 Johnson Craig A · CIK 0001370348 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,292 F3 · shares: The shares were granted as restricted stock units which vest in full on December 22, 2022. Read SEC document |
| December 21, 2021 Filed Dec 23, 2021 23:57 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | SaleCommon Stock | 250 | $9.73 | $2,431.93 |
DisclosureSEC source: 0001209191-21-071169 · doc4.xml · nonDerivative · entry 1 Johnson Craig A · CIK 0001370348 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,840 F1 · kind: The sale of common stock reported in this Form 4 was effected pursuant to a Rule 10b5-1 plan dated as of March 3, 2021. The shares were sold by Mr. Johnson to cover his estimated tax liability associated with the vesting of 750 restricted stock units (RSUs) on December 21, 2021. F2 · price: The range of sales prices received was $9.625 to $9.845. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information will be provided regarding the number of shares purchased or sold at each separate price. Read SEC document |
| September 21, 2021 Filed Sep 23, 2021 20:29 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | SaleCommon Stock | 250 | $12.30 | $3,074.10 |
DisclosureSEC source: 0001209191-21-057419 · doc4.xml · nonDerivative · entry 1 Johnson Craig A · CIK 0001370348 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,090 F1 · kind: The sale of common stock reported in this Form 4 was effected pursuant to a Rule 10b5-1 plan dated as of March 3, 2021. The shares were sold by Mr. Johnson to cover his estimated tax liability associated with the vesting of 750 restricted stock units (RSUs) on September 21, 2021. F2 · price: The range of sales prices received was $12.15 to $12.40. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information will be provided regarding the number of shares purchased or sold at each separate price. Read SEC document |
| June 21, 2021 Filed Jun 22, 2021 21:05 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | SaleCommon Stock | 250 | $15.20 | $3,800.60 |
DisclosureSEC source: 0001209191-21-042429 · doc4.xml · nonDerivative · entry 1 Johnson Craig A · CIK 0001370348 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,340 F1 · kind: The sale of common stock reported in this Form 4 was effected pursuant to a Rule 10b5-1 plan dated as of March 3, 2021. F2 · price: The range of sales prices received was $14.89 to $15.42. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information will be provided regarding the number of shares purchased or sold at each separate price. Read SEC document |
| April 06, 2021 Filed Apr 7, 2021 21:04 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | SaleCommon Stock | 250 | $17.22 | $4,305.20 |
DisclosureSEC source: 0001209191-21-025903 · doc4.xml · nonDerivative · entry 1 Johnson Craig A · CIK 0001370348 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,590 F1 · kind: The sale of common stock reported in this Form 4 was effected pursuant to a Rule 10b5-1 plan dated as of March 3, 2021. F2 · price: The range of sales prices received was $16.98 to $17.48. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information will be provided regarding the number of shares purchased or sold at each separate price. Read SEC document |
| January 21, 2021 Filed Jan 25, 2021 21:31 UTC | Mirati Therapeutics, Inc. MRTX · Entity 94908 | Exercise / conversionNon Qualified Stock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $20.54 | $0.00 |
DisclosureSEC source: 0001214659-21-000756 · marketforms-51235.xml · derivative · entry 8 Johnson Craig A · CIK 0001370348 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires 2024-09-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 12, 2020. F7 · derivative.exercise_date: The shares subject to the Option vest and become exercisable in 12 equal monthly installments following the date of grant. Read SEC document |
| January 21, 2021 Filed Jan 25, 2021 21:31 UTC | Mirati Therapeutics, Inc. MRTX · Entity 94908 | SaleCommon Stock | 334 | $214.75 | $71,727.57 |
DisclosureSEC source: 0001214659-21-000756 · marketforms-51235.xml · nonDerivative · entry 7 Johnson Craig A · CIK 0001370348 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,475 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 12, 2020. F6 · price: This transaction was executed in multiple trades at prices ranging from $214.62 to $215.065. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 21, 2021 Filed Jan 25, 2021 21:31 UTC | Mirati Therapeutics, Inc. MRTX · Entity 94908 | SaleCommon Stock | 44 | $213.62 | $9,399.28 |
DisclosureSEC source: 0001214659-21-000756 · marketforms-51235.xml · nonDerivative · entry 6 Johnson Craig A · CIK 0001370348 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,809 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 12, 2020. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.